PuraPly® Antimicrobial Substantially Reduced MRSA as Compared to Other Products1

A preliminary study evaluated the ability of PuraPly Antimicrobial, PriMatrix® Ag, and Endoform™ to reduce the proliferation of biofilm-associated bacteria (MRSA USA300, a clinically virulent strain of Staphylococcus aureus) in a deep dermal porcine wound model.1 This was a preliminary study with a small sample size, so these observational results are not statistically powered conclusions.

Additional Key Findings1

  • >98% reduction of MRSA counts compared to baseline
  • >96% reduction of MRSA counts vs untreated controls on all assessment days
  • Largest reduction of MRSA counts vs any of the other treatment groups
  • The only treatment to substantially reduce bacterial load within 2 days

Watch the Poster Presentation

Hear principal investigator Stephen C. Davis discuss the details of the preliminary study—exhibited as a poster at SAWC Fall 2017.

In Vitro Scientific Data

In a United States Pharmacopeia Antimicrobial Effectiveness Test, PuraPly Antimicrobial effectively reduced concentrations of Aspergillus niger, Candida albicans, Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli at days 7, 14, and 28.2


References: 1. Davis SC, Gil J, Valdes J, et al. Preliminary evaluation of a purified collagen matrix with polyhexamethylene biguanide (PHMB) antimicrobial reducing methicillin resistant Staphylococcus aureus infections using a porcine deep dermal wound model. Poster presented at: 9th Annual Symposium for Advanced Wound Care; October 20-22, 2017; Las Vegas, NV. 2. Data on file. Organogenesis Inc.